Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Merkel Cells: Modified epidermal cells located in the stratum basale. They are found mostly in areas where sensory perception is acute, such as the fingertips. Merkel cells are closely associated with an expanded terminal bulb of an afferent myelinated nerve fiber. Do not confuse with Merkel's corpuscle which is a combination of a neuron and an epidermal cell.Merkel cell polyomavirus: A species of POLYOMAVIRUS suspected to be the cause of most cases of MERKEL CELL CARCINOMA, a rare but highly lethal form of skin cancer.Skin Neoplasms: Tumors or cancer of the SKIN.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Polyomavirus Infections: Infections with POLYOMAVIRUS, which are often cultured from the urine of kidney transplant patients. Excretion of BK VIRUS is associated with ureteral strictures and CYSTITIS, and that of JC VIRUS with progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL).Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Mohs Surgery: A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.National Cancer Institute (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.Evidence-Based Medicine: An approach of practicing medicine with the goal to improve and evaluate patient care. It requires the judicious integration of best research evidence with the patient's values to make decisions about medical care. This method is to help physicians make proper diagnosis, devise best testing plan, choose best treatment and methods of disease prevention, as well as develop guidelines for large groups of patients with the same disease. (from JAMA 296 (9), 2006)Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.AnilidesReceptor Protein-Tyrosine Kinases: A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.Polyomavirus: A genus of potentially oncogenic viruses of the family POLYOMAVIRIDAE. These viruses are normally present in their natural hosts as latent infections. The virus is oncogenic in hosts different from the species of origin.Urogenital Neoplasms: Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.Hypermedia: Computerized compilations of information units (text, sound, graphics, and/or video) interconnected by logical nonlinear linkages that enable users to follow optimal paths through the material and also the systems used to create and display this information. (From Thesaurus of ERIC Descriptors, 1994)Adaptation, Psychological: A state of harmony between internal needs and external demands and the processes used in achieving this condition. (From APA Thesaurus of Psychological Index Terms, 8th ed)Research: Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)Information Systems: Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.Medical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.Tumor Virus Infections: Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.Sentinel Lymph Node Biopsy: A diagnostic procedure used to determine whether LYMPHATIC METASTASIS has occurred. The sentinel lymph node is the first lymph node to receive drainage from a neoplasm.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.EuropePubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.Foundations: Organizations established by endowments with provision for future maintenance.Medical Indigency: The condition in which individuals are financially unable to access adequate medical care without depriving themselves and their dependents of food, clothing, shelter, and other essentials of living.Occupational Therapy: Skilled treatment that helps individuals achieve independence in all facets of their lives. It assists in the development of skills needed for independent living.DNA Methylation: Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.CpG Islands: Areas of increased density of the dinucleotide sequence cytosine--phosphate diester--guanine. They form stretches of DNA several hundred to several thousand base pairs long. In humans there are about 45,000 CpG islands, mostly found at the 5' ends of genes. They are unmethylated except for those on the inactive X chromosome and some associated with imprinted genes.Promoter Regions, Genetic: DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.Track and Field: Sports performed on a track, field, or arena and including running events and other competitions, such as the pole vault, shot put, etc.Congresses as Topic: Conferences, conventions or formal meetings usually attended by delegates representing a special field of interest.ScandinaviaArchivesBiological Science Disciplines: All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Appendix: A worm-like blind tube extension from the CECUM.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Antigens, CD274: An inhibitory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN. CD274 antigen provides negative signals that control and inhibit T-cell responses and is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.Antigens, Polyomavirus Transforming: Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.KansasCarcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)

Merkel cell carcinoma and melanoma: etiological similarities and differences. (1/218)

Merkel cell carcinoma (MCC) of the skin and cutaneous malignant melanoma can now be compared epidemiologically through the use of population-based data not previously available for MCC. The results may provide new clues to etiology. In this study, United States data covered by the Surveillance, Epidemiology, and End Results (SEER) Program were from nine areas of the United States (approximately 10% of the population). In 1986-1994, 425 cases of MCC were registered. The annual age-adjusted incidence per 100,000 of MCC was 0.23 for whites and 0.01 for blacks; among whites, the ratio of melanoma to MCC was approximately 65 to 1. Only 5% of MCC occurred before age 50, unlike the lifelong risk of nodular and superficial spreading melanoma. Regional incidence rates of both cancers increased similarly with increasing sun exposure as measured by the UVB solar index. The most sun-exposed anatomical site, the face, was the location of 36% of MCC but only 14% of melanoma. Both cancers increased in frequency and aggressiveness after immunosuppression and organ transplantation (36 cases from the Cincinnati Transplant Tumor registry and 12 from published case reports) and after B-cell neoplasia (5 cases in this study; 13 from case series in the literature). The SEER data contained reports of six patients with both types of cancer; 5 melanomas before the diagnosis of MCC and 1 after diagnosis. MCC and melanoma are similarly related to sun exposure and immunosuppression, but they differ markedly from one another in their distributions by age, race, and anatomical site, especially the face.  (+info)

Mutation analysis of P73 and TP53 in Merkel cell carcinoma. (2/218)

The p73 gene has been mapped to 1p36.33, a region which is frequently deleted in a wide variety of neoplasms including tumours of neuroectodermal origin. The p73 protein shows structural and functional homology to p53. For these reasons, p73 was considered as a positional and functional candidate tumour suppressor gene. Thus far, mutation analysis has provided no evidence for involvement of p73 in oligodendrogliomas, lung carcinoma, oesophageal carcinoma, prostatic carcinoma and hepatocellular carcinoma. In neuroblastoma, two mutations have been observed in a series of 140 tumours. In view of the occurrence of 1p deletions in Merkel cell carcinoma (MCC) and the location of p73 we decided to search for mutations in the p73 gene in five MCC cell lines and ten MCC tumours to test potential tumour suppressor function for this gene in MCC. In view of the possible complementary functions of p73 and TP53 we also examined the status of the TP53 gene. Sequence analysis of the entire coding region of the p73 gene revealed previously reported polymorphisms in four MCCs. In one MCC tumour, a mis-sense mutation located in the NH2-terminal transactivation region of the p73 gene was found. These results show that p73, analogous to neuroblastoma, is infrequently mutated in MCC. This is also the first report in which the role of TP53 in MCC has been investigated by sequencing the entire coding region of TP53. TP53 mis-sense mutations and one non-sense mutation were detected in three of 15 examined MCCs, suggesting that TP53 mutations may play a role in the pathogenesis or progression of a subset of MCCs. Moreover, typical UVB induced C to T mutations were found in one MCC cell line thus providing further evidence for sun-exposure in the aetiology of this rare skin cancer.  (+info)

Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. (3/218)

Merkel cell carcinoma was first described in 1972 by Toker and is an aggressive neuroendocrine skin tumor with a high metastatic potential. Merkel cell carcinoma is thought to derive from the neuroendocrine (Merkel) cells of the skin, although in contrast to fetal and especially adult Merkel cells, Merkel cell carcinomas express high levels of the Bcl-2 oncoprotein. Bcl-2 is capable of blocking programmed cell death and has been shown to play an important role in normal cell turnover, tumor biology, and chemoresistance. High Bcl-2 expression leading to prolonged survival of cells may therefore be of importance in the biological and clinical characteristics of Merkel cell carcinoma. In a SCID mouse xenotransplantation model for human Merkel cell carcinoma, we investigated the influence of the bcl-2 antisense oligonucleotide G3139 (Genta) on tumor growth in comparison with control oligonucleotides or cisplatin. Bcl-2 antisense treatment, targeting the first six codons of the bcl-2 mRNA, resulted in either a dramatic reduction of tumor growth or complete remission, whereas reverse sequence and two-base mismatch control oligonucleotides or cisplatin had no significant antitumor effects compared with saline-treated controls. Apoptosis was enhanced 2.4-fold in the bcl-2 antisense treated tumors compared with the saline-treated group, and no other treatment showed a comparable increase in apoptosis. Our findings suggest that bcl-2 antisense treatment may be a novel approach to improve treatment outcome of human Merkel cell carcinoma.  (+info)

Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. (4/218)

PURPOSE: To study the use of chemotherapy for Merkel cell carcinoma (MCC) of the skin. PATIENTS AND METHODS: Twenty-five cases of MCC were treated at the London Regional Cancer Center between 1987 and 1997. Thirteen cases treated with chemotherapy were reviewed with 191 cases from the literature. RESULTS: At presentation, 24 patients had localized skin lesions (stage I) and one had locoregional involvement (stage II). Among the nine cases with recurrent nodal disease, six had chemotherapy as a component of salvage treatment. They were all free of disease at a median of 19 months (range, 12 to 37 months). In contrast, two patients who had salvage radiotherapy alone died of disease. Overall survival (OS) and disease-free survival (DFS) were 59% and 43%, respectively, at two years. Median OS and DFS were 29 months (range, 1 to 133 months) and 9 months (range, 1 to 133 months), respectively. Nodal disease developed in 12 (50%) of 24 patients with stage I disease, and distant metastases developed in six (25%) of 24. Including those from the literature, there were 204 cases treated with chemotherapy. Cyclophosphamide/doxorubicin (or epirubicin)/vincristine combination +/- prednisone was the most commonly used chemotherapy regimen (47 cases), with an overall response rate of 75.7% (35.1% complete, 35. 1% partial, and 5.4% minor responses). Etoposide/cisplatin (or carboplatin) was the next most commonly used regimen (27 cases), with an overall response rate of 60% (36% complete and 24% partial responses). The difference in response rate was not statistically significant (P =.19). Among the 204 cases, there were seven (3.4%) toxic deaths. CONCLUSION: Chemoradiation for locally recurrent or advanced disease may be an option for patients with a good performance status.  (+info)

Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. (5/218)

This study sought to use a microdialysis technique to relate clinical and biochemical responses to the time course of melphalan concentrations in the subcutaneous interstitial space and in tumour tissue (melanoma, malignant fibrous histiocytoma, Merkel cell tumour and osteosarcoma) in patients undergoing regional chemotherapy by Isolated Limb Infusion (ILI). 19 patients undergoing ILI for treatment of various limb malignancies were monitored for intra-operative melphalan concentrations in plasma and, using microdialysis, in subcutaneous and tumour tissues. Peak and mean concentrations of melphalan were significantly higher in plasma than in subcutaneous or tumour microdialysate. There was no significant difference between drug peak and mean concentrations in interstitial and tumour tissue, indicating that there was no preferential uptake of melphalan into the tumours. The time course of melphalan in the microdialysate could be described by a pharmacokinetic model which assumed melphalan distributed from the plasma into the interstitial space. The model also accounted for the vascular dispersion of melphalan in the limb. Tumour response in the whole group to treatment was partial response: 53.8% (n = 7); complete response: 33.3% (n = 5); no response: 6.7% (n = 1). There was a significant association between tumour response and melphalan concentrations measured over time in subcutaneous microdialysate (P< 0.01). No significant relationship existed between the severity of toxic reactions in the limb or peak plasma creatine phosphokinase levels and peak melphalan microdialysate or plasma concentrations. It is concluded that microdialysis is a technique well suited for measuring concentrations of cytotoxic drug during ILI. The possibility of predicting actual concentrations of cytotoxic drug in the limb during ILI using our model opens an opportunity for improved drug dose calculation. The combination of predicting tissue concentrations and monitoring in microdialysate of subcutaneous tissue could help optimise ILI with regard to post-operative limb morbidity and tumour response.  (+info)

Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. (6/218)

BACKGROUND: Somatostatin receptor scintigraphy (SRS) may be of interest for staging Merkel Cell Carcinoma (MCC). This study was undertaken to evaluate the sensitivity and specificity of SRS and to determine its role compared to conventional investigations. PATIENTS AND METHODS: From 1993 to December 2000, 20 patients (10 females and 10 males, aged from 38 to 88, mean 66 years) were included prospectively. At the time of SRS: 12 patients had been diagnosed as having stage I disease, 6 stage II and 4 stage III. Two patients had two SRS studies during the course of their disease. SRS was performed with Indium-111 pentetreotide (Octreoscan), a radiolabelled somatostatin analogue. Patients were treated according to the clinical stage. A regular follow-up was scheduled every three months. RESULTS: SRS depicted stage I and II MCC tumour sites with an overall sensitivity of 78% (95% confidence interval (CI): 40%-97%) and a specificity of 96% (81%-100%). The histopathological diagnosis was used as the gold standard. Sites visualised by SRS were compared to those detected with conventional modalities and to follow-up data for all stages: SRS visualised four out of five primary tumour sites, six out of eight lymph node sites, no skin metastases (14 sites in 2 patients), two out of three thoracic metastases and zero out of two hepatic metastases. SRS did not influence treatment decision-making in any of the cases. CONCLUSIONS: Although SRS seems highly specific in MCC and could be of help in difficult cases, it cannot be recommended for routine evaluation.  (+info)

Merkel cell carcinoma: a rare cause of hypervascular nasal tumor. (7/218)

Cutaneous neuroendocrine carcinoma, first described in 1972, is an aggressive disease usually occurring in sun-exposed skin. Other sites have been described, however; such tumors occasionally occur within the nasal fossa. A high rate of metastasis (>30%) explains the poor prognosis. Descriptions of the imaging features of these tumors, mainly located in cutaneous region, are rare. We therefore present the imaging features of two cases of Merkel cell carcinoma involving the sinonasal region, suggestive of a hypervascular tumor.  (+info)

Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1. (8/218)

AIM: To investigate whether immunohistochemical staining for cytokeratin 20 (CK20) and thyroid transcription factor 1 (TTF-1) is useful in distinguishing Merkel cell carcinomas (MCCs) from metastatic small cell carcinomas (SCCs). METHODS: Eleven cases of MCC and 10 of lung SCC were stained for CK20 and TTF-1. RESULTS: Ten of 11 MCCs stained with the antibody to CK20. None was positive for TTF-1. No SCC stained with anti-CK20 and all stained strongly with anti-TTF-1. CONCLUSIONS: The use of both anti-CK20 and anti-TTF-1 can reliably distinguish between MCC and metastatic SCC, thus avoiding the need for a detailed clinical investigation of patients with MCC in whom metastatic SCC must be excluded.  (+info)

*Smallpox

... the virus seemed to move from cell to cell, but by around the 12th day, lysis of many infected cells occurred and the virus was ... ACAM2000s virus is cultured in kidney epithelial cells (Vero cells) from an African green monkey. Efficacy and adverse reaction ... Merkel cell polyomavirus *Merkel cell carcinoma. RNA virus. Paramyxoviridae. *MeV *Measles. Togaviridae. *Rubella virus * ... Poxviruses are unique among DNA viruses in that they replicate in the cytoplasm of the cell rather than in the nucleus. In ...

*Molluscum contagiosum

squamous-cell carcinoma. *basal-cell carcinoma. *Merkel-cell carcinoma. *nevus sebaceous. *trichoepithelioma ... Potential systemic absorption of imiquimod, with negative effects on white blood cell counts overall, and specifically ... which consist of large cells with abundant granular eosinophilic cytoplasm (accumulated virions) and a small peripheral nucleus ...

*Chickenpox

squamous-cell carcinoma. *basal-cell carcinoma. *Merkel-cell carcinoma. *nevus sebaceous. *trichoepithelioma ... Cell-mediated immune responses are also important in limiting the scope and the duration of primary varicella infection. After ... VZV then remains latent in the dorsal ganglion cells of the sensory nerves. Reactivation of VZV results in the clinically ...

*Kaposi's sarcoma-associated herpesvirus

"KSHV Entry and Trafficking in Target Cells-Hijacking of Cell Signal Pathways, Actin and Membrane Dynamics". Viruses. 8 (11): ... Merkel cell polyomavirus *Merkel cell carcinoma. RNA virus. Paramyxoviridae. *MeV *Measles. Togaviridae. *Rubella virus * ... Once the virus newly infects a cell, the lipid membrane is shed and the virion travels to the nucleus. The viral genome is ... KSHV is a rhadinovirus, and is remarkable since it has stolen numerous genes from host cells including genes that encode for ...

*Plantar wart

Callus, molluscum contagiosum, squamous cell carcinoma[2]. Treatment. Salicylic acid, cryotherapy, surgical removal[2]. ... Salicylic acid - the treatment of warts by keratolysis involves the peeling away of dead surface skin cells with keratolytic ... is a common surgical treatment which acts by freezing the external cell structure of the warts, destroying the live tissue. ...

*Herpes gladiatorum

The virus infects the cells in the epidermal layer of the skin. The initial viral replication occurs at the entry site in the ... Merkel cell polyomavirus *Merkel cell carcinoma. RNA virus. Paramyxoviridae. *MeV *Measles. Togaviridae. *Rubella virus * ... The virus moves to the nerve cells from where it can reactivate. Once the condition has recurred, it is normally a mild ... and then it goes to the nuclei of the cells and reproduces or replicates.[9] The blisters and ulcers formed on the skin are a ...

*Scarlet fever

Merkel cell polyomavirus *Merkel cell carcinoma. RNA virus. Paramyxoviridae. *MeV *Measles. Togaviridae. *Rubella virus * ... George and Gladys Dick showed that cell-free filtrates could induce the erythematous reaction characteristic of scarlet fever, ... because they are able to cause an extensive immune response within the body through activation of some of the main cells ...

*Herpangina

Malignant: Adenosquamous carcinoma. *Basaloid squamous carcinoma. *Mucosal melanoma. *Spindle cell carcinoma. *Squamous cell ... Histologically, the epithelial cells show signs of intracellular and extracellular edema.[citation needed] ...

*Herpes labialis

Malignant: Adenosquamous carcinoma. *Basaloid squamous carcinoma. *Mucosal melanoma. *Spindle cell carcinoma. *Squamous cell ... Inflammation (day 1): Virus begins reproducing and infecting cells at the end of the nerve. The healthy cells react to the ... Post-scab (12-14 days): A reddish area may linger at the site of viral infection as the destroyed cells are regenerated. Virus ...

*Orf (disease)

Merkel cell polyomavirus *Merkel cell carcinoma. RNA virus. Paramyxoviridae. *MeV *Measles. Togaviridae. *Rubella virus * ...

*Roseola

Merkel cell polyomavirus *Merkel cell carcinoma. RNA virus. Paramyxoviridae. *MeV *Measles. Togaviridae. *Rubella virus * ... Low numbers of white blood cells may also be present.[1] ...

*Murad Alam

"Merkel cell carcinoma". Journal of the National Comprehensive Cancer Network. 7 (3): 322-32. PMID 19401064. Alam, Murad; ... His work has also extended to serving on expert panels such as those dedicated to merkel cell cancer and guidelines of care. He ... Alam, Murad; Ratner, Désirée (2001). "Cutaneous Squamous-Cell Carcinoma". New England Journal of Medicine. 344 (13): 975-83. ...

*Azzopardi phenomenon

Vazmitel M, Michal M, Kazakov DV (2007). "Merkel cell carcinoma and Azzopardi phenomenon". Am J Dermatopathol. 29 (3): 314-5. ... It can occur in small cell carcinomas and in some high-grade malignant neoplasms. The effect is well known in diagnostic ... Azzopardi JG (1959). "Oat-cell carcinoma of the bronchus". J Pathol Bacteriol. 78: 513-9. PMID 13795444. Warnock ML, McCowin MJ ... Case Studies Azzopardi phenomenon in a metastatic small cell carcinoma of the lung. ...

*Alexander Younger

"Overview - Merkel cell carcinoma - Mayo Clinic". www.mayoclinic.org. "Michael Wilson, former finance minister, ambassador, to ...

*Morten Frisch

"Merkel cell carcinoma and HIV infection." The Lancet 359, no. 9305 (2002): 497-498. "Morten Frisch". SSI. Retrieved 21 August ...

*Human papillomavirus infection

Merkel-cell carcinoma. RNA virus. HCV Hepatocellular carcinoma. Splenic marginal zone lymphoma. HTLV-I Adult T-cell leukemia/ ... Studies have found heightened HPV in mouth cell samples from people with squamous cell carcinoma of the mouth. Studies have not ... Thus, inactivation of p53 by E6 can promote unregulated cell division, cell growth, and cell survival, characteristics of ... "Genus β human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control ...

*Pembrolizumab

Results of a Phase II clinical trial in Merkel-cell carcinoma were reported in the New England Journal of Medicine in June 2016 ... Nghiem (2016). "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma". N. Engl. J. Med. 374 (26): 2542-2552. doi: ... Fuereder, Thorsten (20 June 2016). "Immunotherapy for head and neck squamous cell carcinoma". memo - Magazine of European ... It blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the ...

*Infectious causes of cancer

About 80% of Merkel cell carcinomas are caused by Merkel cell polyomavirus; the remaining tumors have an unknown etiology and ... Merkel cell polyomavirus is the most recently discovered human cancer virus, isolated from Merkel cell carcinoma tissues in ... Feng, H; Shuda, M; Chang, Y; Moore, P. S. (2008). "Clonal integration of a polyomavirus in human Merkel cell carcinoma". ... hepatocellular carcinoma), and Human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk ...

*Large tumor antigen

... naturally infects humans and is associated with Merkel cell carcinoma (MCC), a rare form of skin cancer originating from Merkel ... of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells". Cell. ... "Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma". Science. 319 (5866): 1096-1100. doi:10.1126/science. ... the cell must be in S phase (the part of the cell cycle in which the host cell's genome is normally replicated) in order to ...

*Digital transcriptome subtraction

... and was used to discover Merkel cell polymavirus in Merkel cell carcinoma. Simultaneously to the MCV discovery, this approach ... Feng H, Shuda M, Chang Y, Moore PS (Jan 2008). "Clonal integration of a polyomavirus in human Merkel cell carcinoma". Science. ... the suspect causative agent in Merkel cell carcinoma. Using computational subtraction to discover novel pathogens was first ... The method specifically examines the etiological agent of infectious diseases and is best known for discovering Merkel cell ...

*Patrick S. Moore

This virus is the likely cause of Merkel-cell carcinoma and hence is named Merkel cell polyomavirus. Moore and Chang have ... Feng H, Shuda M, Chang Y, Moore PS (February 2008). "Clonal integration of a polyomavirus in human Merkel cell carcinoma". ... two different human viruses causing the AIDS-related cancer Kaposi's sarcoma and the skin cancer Merkel cell carcinoma. The ... they identified the most recently discovered human polyomavirus infecting Merkel cells. ...

*Oncovirus

DTS was used to isolate DNA fragments of Merkel cell polyomavirus from a Merkel cell carcinoma and it is now believed that this ... but a recently discovered analogue called Merkel cell polyomavirus has been associated with Merkel cell carcinoma, a form of ... Feng H, Shuda M, Chang Y, Moore PS (February 2008). "Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma". ... Forcing the cell into the S phase of the cell cycle could cause the cell to become transformed. Some types of HPV increase the ...

*தோல் புற்றுநோய் - தமிழ் விக்கிப்பீடியா

Merkel cell carcinoma = மேர்கேல் உயிரணுப் புற்றுநோய். *Kaposi's sarcoma = காபோசியின் சதைப்புற்று. *keratoacanthoma = கொம்புமுட் ... basal cell carcinoma), செதிட்கலப் புற்றுநோய் (Squamous cell carcinoma), மெலனோமா அல்லது கரிநிறமிப் புற்றுநோய். இவை ஒவ்வொன்றும் ... basal cell carcinoma), செதிட்கலப் புற்றுநோய் (Squamous cell carcinoma), மெலனோமா அல்லது கரிநிறமிப் புற்றுநோய் (melanoma). ... அடிக்கலப் புற்றுநோய் (basal cell carcinoma). முத்துப்போன்ற பளபளக்கும் திரளையாகக் காணப்படுவதையும், சிறிய ...

*Tumor antigens recognized by T lymphocytes

... and Epstein-Barr virus causing B cell lymphomas and nasopharyngeal carcinomas. Kaposi sarcoma virus and Merkel cell polyoma ... T lymphocytes are cells of the immune system that attack and destroy virus-infected cells, tumor cells and cells from ... The carcinoma cells still harbour the viral genes and antigens. As expected T cell responses against antigens encoded by genes ... This enables the T cells to eliminate cells with "foreign" or "abnormal" antigens without harming the normal cells. It has long ...

*Lorvotuzumab mertansine

... small-cell lung cancer, ovarian cancer). It has been granted Orphan drug status for Merkel cell carcinoma. It has reported ... It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a ... "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung ... encouraging Phase II results for small-cell lung cancer. Dimond (9 Mar 2010). "Antibody-Drug Conjugates Stage a Comeback". ...

*Oncovirus

Merkel-cell carcinoma. RNA virus. HCV Hepatocellular carcinoma. Splenic marginal zone lymphoma. HTLV-I Adult T-cell leukemia/ ... Merkel cell polyomavirus (MCV). NA. Merkel cell carcinoma. Epstein-Barr virus (EBV). NA. Burkitt's lymphoma, Hodgkin's lymphoma ... Merkel cell polyomavirus - a polyoma virus - is associated with the development of Merkel cell carcinoma[27] ... DTS was used to isolate DNA fragments of Merkel cell polyomavirus from a Merkel cell carcinoma and it is now believed that this ...

*Alpha-1 antitrypsin

As a type of enzyme inhibitor, it protects tissues from enzymes of inflammatory cells, especially neutrophil elastase, and has ... Mahr AD, Neogi T, Merkel PA (2006). "Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of ... Rudnick DA, Perlmutter DH (September 2005). "Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in ... which could confer this protein particular protein-cell recognition properties. The single cysteine residue of A1AT in position ...

*PD-1 and PD-L1 inhibitors

Avelumab has been FDA approved for the treatment of metastatic Merkel-cell carcinoma. It failed phase III clinical trials for ... It was later approved for metastatic non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma. In 2017, it ... It was later approved for squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. As of 2017, four PD-1 ... In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals ...
Merkel cell carcinoma is a rare and aggressive skin malignancy that arises from primary neural cells and has a tendency for local recurrence and regional lymph node metastases. There are only a few cases in the literature reporting metastases of Merkel cell carcinoma to the gastrointestinal tract. We present a 70 year old Caucasian female with distant history of Merkel cell carcinoma who presented with iron-deficiency anemia. Colonoscopy performed later for the evaluation of anemia revealed 1 cm polyp in ascending colon which turned out to be the recurrence of Merkel cell carcinoma. Metastatic Merkel cell carcinoma to the gastrointestinal tract or any other organ should be considered in patients with a history of Merkel cell carcinoma.
So these are the characteristics of the 88 patients treated. You can see 25% of the patients were under 65, the vast majority of patients were over the age of 65, consistent with the clinical course of Merkel cell carcinoma. 74% of the patients were men, most had good ECOG performance status. Not surprisingly, 76% of the patients presented with a primary cutaneous Merkel cell carcinoma but some patients their initial presentation was in the lymph node or other sites. Although 59% of the patients had one prior therapy its important to note that 35% of this population had actually failed two or more lines of prior therapy so this is a fairly advanced group. 53% of the patients had evidence of visceral metastases at the study entry and 21% had only lymph node disease at the time they entered.. We also looked at the tumour burden to see if that might be an independent predictor of response, so that data is shown there. We basically measured the sum of the longest diameters of all the index lesions ...
Avelumab showed early positive survival data and lasting responses for patients with pretreated advanced or metastatic Merkel cell carcinoma, according to findings from the phase II JAVELIN Merkel 200 trial presented at the 2016 ASCO Annual Meeting.
Primary: To compare the efficacy, as measured by objective response rate (ORR), provided by nivolumab plus ipilimumab with or without SBRT in subjects with metastatic Merkel cell carcinoma. Secondary: To compare the progression free survival (PFS) of nivolumab and ipilimumab versus SBRT plus nivolumab and ipilimumab in subjects with metastatic Merkel cell carcinoma. To compare the overall survival (OS) of nivolumab and ipilimumab versus SBRT plus nivolumab and ipilimumab in subjects with metastatic Merkel cell carcinoma. To evaluate the local control of irradiated tumor provided by SBRT in combination with nivolumab and ipilimumab. To assess the overall safety and tolerability of of nivolumab and ipilimumab versus SBRT plus nivolumab and ipilimumab in subjects with metastatic Merkel cell carcinoma. To evaluate whether PD-L1 expression is a predictive biomarker for ORR. To evaluate the Health Related Quality of Life (HRQoL) as assessed by European Organisation for Research and Treatment of Cancer ...
On September 24, 2017, Posted by Birgit Rogell , In Press Releases, With Kommentare deaktiviert für Merck: European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma ...
TY - JOUR. T1 - Merkel cell carcinoma. T2 - Diagnosis, management, and outcomes. AU - Senchenkov, Alex. AU - Moran, Steven Lawrence. PY - 2013/5. Y1 - 2013/5. N2 - Merkel cell carcinoma is a rare, aggressive cutaneous malignancy with high rates of recurrence, metastases, and mortality. Its nonspecific clinical presentation often delays the diagnosis, and its treatment is still controversial because of the infrequent nature of the tumor. The authors provide an overview of the current literature on epidemiology, cause, pathogenesis, staging, management, and outcomes of this disease. Effective diagnostic and treatment modalities such as wide local excision of the primary tumor, importance of sentinel node biopsy for staging, evidence for the use of adjuvant radiation therapy, and emphasis on a multidisciplinary treatment approach of Merkel cell carcinoma as it pertains to surgical practice are reviewed.. AB - Merkel cell carcinoma is a rare, aggressive cutaneous malignancy with high rates of ...
Merkel cell carcinoma (MCC) is a rare form of skin cancer, often described as the most aggressive cutaneous malignancy. Its high propensity for dermal-lymphatic invasion, local recurrence, and rapid lymphatic and distant metastasis poses a significant treatment challenge to clinicians. Combining its highly aggressive nature with its low incidence, merkel cell carcinoma is a particularly difficult cancer to study. Two major staging criteria exist for Merkel cell carcinoma. The purpose of this study is to validate and compare the Memorial Sloan Kettering Cancer Center (MSKCC) staging criteria with the American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis (TNM) staging criteria for Merkel cell carcinoma (MCC) utilizing the Surveillance, Epidemiology, and End Results (SEER) database. The role of radiation therapy (RT) is also evaluated. 1556 cases of MCC from the SEER database (1988-2002) were identified and evaluated. Tumor size, lymph node status, and metastases were staged according to the
Merkel cell carcinoma is a malignant skin tumor with a poor prognosis that primarily affects photoexposed areas of elderly patients. Tumor size is a very strong prognostic factor, with much better outcomes associated with small lesions, measuring less than 1cm. However, such lesions are rarely seen in the clinic in view of the rapid growth of this tumor. We report 2 cases of incipient Merkel cell carcinoma. Both cases of incipient Merkel cell carcinoma measured approximately 5mm in diameter. One tumor was confined to the epidermis and papillary dermis on the nose of a 79-year-old man and the other was located in the deep dermis, almost in the hypodermis, on the buttock of an 82-year-old woman. In both cases, the lesions had appeared weeks earlier. The first tumor seemed to originate in the dermoepidermal junction whereas the second originated almost in the hypodermis. Although the lesions were at a similar disease stage and had a similar size, their different locations within the dermis ...
Merkel cell carcinoma commonly present on the extremities and the head. Merkel cell carcinoma is a form of subcutaneous to cutaneous papule or nodule. Merkel cell carcinoma is a red, violet,pink or reddish brown dome shaped lesion.
Find the best merkel cell carcinoma doctors in Navi Mumbai. Get guidance from medical experts to select merkel cell carcinoma specialist in Navi Mumbai from trusted hospitals - credihealth.com
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer associated with advanced age and immunosuppression. Over the past decade, an association has been discovered between MCC and either integration of the Merkel cell polyomavirus, which likely drives tumorigenesis, or somatic mutations owing to ultraviolet-induced DNA damage. Both virus-positive and virus-negative MCCs are immunogenic, and inhibition of the programmed cell death protein 1 (PD-1)-programmed cell death 1 ligand 1 (PD-L1) immune checkpoint has proved to be highly effective in treating patients with metastatic MCC; however, not all patients have a durable response to immunotherapy. Despite these rapid advances in the understanding and management of patients with MCC, many basic, translational and clinical research questions remain unanswered. In March 2018, an International Workshop on Merkel Cell Carcinoma Research was held at the US National Cancer Institute, at which academic, government and industry experts met to ...
Given the lack of effective treatment options for patients with metastatic Merkel cell carcinoma whose cancer has recurred after chemotherapy, we are excited to see such a high objective response rate. It is also noteworthy that nearly all of the patients whose cancer initially responded to avelumab exhibited durable responses, with most ongoing for more than a year," continued Kaufman, who is also professor of surgery and medicine at the Rutgers Robert Wood Johnson Medical School. "Based on data from this clinical trial, avelumab became the first ever treatment approved by the U.S. Food and Drug Administration for treating patients with this devastating disease.". Kaufman explained that avelumab targets the PD-L1 protein and that the rationale for treating patients with Merkel cell carcinoma with the immunotherapeutic came from studies showing that PD-L1 is found on tumor samples from nearly all patients with this form of cancer.. Kaufman and colleagues enrolled 88 patients with metastatic ...
Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma (skin cancer) in adults
So you might say this would be a great test, but we dont use it in our patients. Why not? Because it makes no difference therapeutically to the one in five patients who has this favorable CD8 profile. Such patients need to receive the same treatment as other patients, regardless of CD8 infiltration status. Disease can recur in such patients, but if it does, we can cure it. Because the CD8 profile really doesnt change our management, we dont routinely do this test.. Optimal Management. Whats the optimal approach, then, for managing the newly diagnosed Merkel cell carcinoma patient? In most cases of Merkel cell carcinoma (about 80%), Merkel cell polyomavirus is clonally integrated in the tumor cells, and viral oncoproteins drive oncogenesis. There is increasing evidence that these patients do somewhat better than polyomavirus-negative patients. What this means clinically is that the 20% of patients who are virus-negative might need more careful monitoring for recurrence.. Several early ...
Business Wire IndiaMerck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer
Treatment of 26 patients with advanced previously untreated Merkel cell carcinoma with Keytruda® (pembrolizumab) every three weeks resulted in an overall response rate of 56% suggesting this novel therapy could represent a new treatment option for these hard to treat cancers. Merkel cell carcinoma is a rare aggressive skin cancer with limited treatment options for […]. ...
We have recently discovered a new human polyomavirus monoclonally-integrated into human Merkel cell carcinomas (MCC) that we call Merkel cell polyomavirus (MCPy...
Sentinel lymph node biopsy (SLNB) is commonly recommended for patients with primary Merkel cell carcinoma (MCC). However, it is critically discussed whether survival rates improve by SLNB in MCC patients in general or in subgroups of higher risk (e.g. with primary tumor size ,1 cm). The present study correlates clinical data, histology and lymph node status with follow-up and survival data to see if subgroups can be identified for modification of the current recommendations. The medical records of 47 patients with histologically confirmed MCC treated between 1995 and 2010 at a German dermatosurgery department were reviewed. Nineteen patients with excision of the primary tumor and SLNB were compared to 28 patients with excision of the primary tumor but without SLNB. End-points of this study were disease-free survival (DFS) and overall survival (OS). In addition, clinical course was correlated with tumor size and size of safety margin. The group of patients who received SLNB showed a significant ...
Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimal management of Merkel cell carcinoma. These areas of uncertainty include early recognition features; clinical and histopathologic prognostic factors; optimum margins of excision of the primary tumor; indications for and value of surgical staging of the clinically negative regional nodes; optimum management of the patient with pathologically positive regional nodes; and indications for and value of radiation to the primary and regional nodes. Through identifying and elaborating on these areas of uncertainty, the authors hope to foster additional research and ultimately improve the evidence base for future iterations of the NCCN Clinical Practice Guidelines in Oncology in this rare but increasingly encountered cutaneous malignancy. The intent, however, is not to exhaustively identify all areas of controversy, ...
At Moffitt Cancer Center, our oncologists can expertly diagnose any patient who presents with the signs of Merkel cell carcinoma, then stage the cancer following a diagnosis, as we have extensive experience treating even the rarest forms of skin cancer. Appointments are available with or without a physicians referral.. Our oncologists can provide additional information about the Merkel cell carcinoma staging process and the treatment options available for metastatic and non-metastatic skin cancers. To schedule a consultation, call 1-888-663-3488 or submit a new patient registration form online.. ...
Merkel cell carcinoma is a rare and aggressive malignancy of the skin. Approximately 2000 cases of Merkel cell carcinoma have been reported since its first publ
What is Merkel Cell Carcinoma? Get the facts about Merkel Cell Carcinoma symptoms, testing, treatment and care options from trusted sources.
NEW YORK, June 29, 2017 /PRNewswire/ -- Merkel Cell Carcinoma - Pipeline Review, H1 2017. Merkel Cell Carcinoma - Pipeline Review, H1 2017.
Merkel cell carcinoma (also known as a "Cutaneous apudoma," "Primary neuroendocrine carcinoma of the skin," Primary small cell carcinoma of the skin, and "Trabecular carcinoma of the skin is a rare and highly aggressive cancer in which malignant cancer cells develop on or just beneath the skin and in hair follicles.. • The majority of Merkel cell carcinomas appear to be caused in part by a newly discovered virus, Merkel cell polyomavirus or MCV. Direct evidence for this comes from studies showing that inhibition of MCV proteins causes MCV-infected Merkel carcinoma cells to die but has no effect on tumor cells from Merkel cell carcinomas that are not infected with the virus. • This cancer is a type of neuroendocrine tumor, like small cell lung cancer. Once it has metastasized to the lymph nodes, the 5-year survival rate for a patient is about 50 percent. A patient with a small tumor (less than 2 cm) that has not metastasized to the lymph nodes may have a 5-year survival rate of more than 80 ...
The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Cabozantinib (XL184) is an inhibitor of multiple receptor tyrosine kinases and was approved by the U.S. Food and Drug Administration (FDA) on 29 November 2012 for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is commercially available as COMETRIQ™ in the United States.. During the Pre Treatment Period, participants are consented and qualified (screened) for the study. Treatment will be administered on an outpatient basis.. Each treatment cycle lasts 28 days, during which time the participant will be taking the study drug, cabozantinib, once daily. The participant will be given a study drug-dosing diary for each treatment cycle. The diary will also include special instructions for taking the study drug.. - Participants will be followed for 8 weeks after removal from study or until death, whichever occurs first. Participants removed from study for unacceptable adverse events will be followed until resolution or stabilization of the adverse event. ...
Merkel cell carcinoma (MCC) is one of the most aggressive cancers of the skin. RASSFs are a family of tumor suppressors that are frequently inactivated by promoter hypermethylation in various cancers. We studied CpG island promoter hypermethylation in MCC of RASSF2, RASSF5A, RASSF5C and RASSF10 by combined bisulfite restriction analysis (COBRA) in MCC samples and control tissue. We found RASSF2 to be methylated in three out of 43 (7%), RASSF5A in 17 out of 39 (44%, but also 43% in normal tissue), RASSF5C in two out of 26 (8%) and RASSF10 in 19 out of 84 (23%) of the cancer samples. No correlation between the methylation status of the analyzed RASSFs or between RASSF methylation and MCC characteristics (primary versus metastatic, Merkel cell polyoma virus infection, age, sex) was found. Our results show that RASSF2, RASSF5C and RASSF10 are aberrantly hypermethylated in MCC to a varying degree and this might contribute to Merkel cell carcinogenesis.
Merkel cell carcinoma (MCC) was originally described by Toker in 1972 as trabecular carcinoma of the skin.[1] Other names include Toker tumor, primary small cell carcinoma of the skin, primary cutaneous neuroendocrine tumor, and malignant trichodiscoma.[2] MCC is an aggressive neuroendocrine carcinoma arising in the...
Background: There are limited data on the travel burden for cancer patients with rare tumor types, such as Merkel cell carcinoma (MCC).. Objective: The objective of this study was to understand the travel burden of MCC patients.. Methods: This study used data from an MCC registry at the Seattle Cancer Care Alliance (SCCA). All MCC patients enrolled at SCCA with a valid 3-digit ZIP code were included. Patients were followed up from January 1, 2012 until their last follow-up, death, or end of data (January 1, 2017). Travel burden was measured by one-way travel distance to SCCA from each patients 3-digit ZIP code. Patient demographics, tumor characteristics, and follow-up visit were evaluated and stratified by one-way driving distance of ≤300 and ,300 miles.. Results: A total of 391 MCC patients were included (68% men, mean age = 67 years [±SD = ±11 years], 67% residing in the West, and 70% white). At diagnosis, 53% of the patients had Stage III or IV MCC. Mean one-way distance traveled by ...
An NCI Cancer Currents blog post about results from a phase II clinical trial showing durable tumor responses to the immunotherapy drug avelumab in patients with metastatic Merkel cell carcinoma.
The ICD-10 Code C7B.1 is the code used for Secondary Merkel cell carcinoma .An alternative description for this code is Secondary Merkel cell ...
Merkel cell carcinoma is an aggressive neuroendocrine cutaneous malignancy with a predilection for regional and distant metastasis. This malignancy presents most commonly on the head and neck of elderly Caucasian males, with a higher prevalence in the immunosuppressed. A high index of suspicion must be maintained due to the often asymptomatic presentation. Lip tumors, scalp tumors, local invasion, nodal metastasis, distant metastasis, and lymphovascular invasion are poor prognostic factors. Up to 8.7% of patients present with distant metastasis, and PET-CT is an accurate staging tool with a 90% sensitivity. Combined aggressive surgical resection with adjuvant radiotherapy affords the best regional control rates. The regional lymphatics must be addressed with either sentinel lymph node biopsy, surgery, or elective radiation due to the risk of occult metastasis. Addition of chemotherapy has no proven benefit in locoregional control.
A human polyomavirus was recently discovered in Merkel cell carcinoma (MCC) specimens. The Merkel cell polyomavirus (MCPyV) genome undergoes clonal integration into the host cell chromosomes of MCC tumors and expresses small T antigen and truncated large T antigen. Previous studies have consistently reported that MCPyV can be detected in approximately 80% of all MCC tumors. We sought to increase the sensitivity of detection of MCPyV in MCC by developing antibodies capable of detecting large T antigen by immunohistochemistry. In addition, we expanded the repertoire of quantitative PCR primers specific for MCPyV to improve the detection of viral DNA in MCC. Here we report that a novel monoclonal antibody detected MCPyV large T antigen expression in 56 of 58 (97%) unique MCC tumors. PCR analysis specifically detected viral DNA in all 60 unique MCC tumors tested. We also detected inactivating point substitution mutations of TP53 in the two MCC specimens that lacked large T antigen expression and in ...
The researchers say that the test is not practical for the initial diagnosis of MCC because the disease is so uncommon; instead, its main use is to detect recurrences earlier.. The test has different implications for MCC patients who do not produce these antibodies - nearly half of those in the study. It doesnt track Merkel cell carcinoma recurrence in this group, because such patients will not produce these antibodies even when the cancer returns. Still, getting the test done once is useful for all patients, including those found not to produce the antibodies. Because those who test negative are 42 percent more likely to have a recurrence, doctors should order more frequent imaging for them. When the recurring MCC is caught early, these patients may particularly benefit from immune therapy. The importance of this test goes beyond the improvement in treatment for patients with MCC. The findings highlight how monitoring the robustness of the immune system provides key insights into cancer ...
Best was diagnosed with cancer in May 2013, when her son was just 5 years old. Although the site of the original cancer could not be determined, over time it became clear that Merkel cell carcinoma was the most likely diagnosis. Within a year of her diagnosis, Best had run out of treatment options, but she was not willing to give up. Intensive research and perseverance led her to Kaufman, and she became the first person to receive avelumab through the JAVELIN Merkel 200 clinical trial in July 2014.. Just six weeks later, after three treatments with the investigational immunotherapeutic, Best learned that her tumors were all gone. She continued to receive avelumab through the clinical trial for several months, but discontinued treatment in May 2015 when the research team felt confident that she no longer needed it.. "Avelumab not only saved my life, it restored my quality of life," said Best in an interview. "Im back to riding my bike with my husband and son, I went skiing this past winter, and ...
Introduction: Merkel cell carcinoma (MCC) of the skin is a rare neuroendocrine tumor characterized by its rapid growth and aggressive clinical behavior. MCC is a typical tumor of older age (average age is 65 years). In children and adolescents less than 20 years of age, it is extremely rare. Information regarding MCC in childhood can be found in the literature only in the form of individual case reports. Due to the rarity of MCC in the young population, any clinical studies or treatment recommendations in these patients are missing ...
A sentinel lymph node biopsy (SLNB) is a common way to determine whether Merkel cell carcinoma (MCC) has reached the lymph nodes.
Merkel cell carcinoma (MCC) is an uncommon and aggressive cutaneous neoplasm; distant metastases are nearly always fatal. How much do you know about MCC? Test yourself with this short quiz.
Merkel cell carcinoma is an especially deadly form of skin cancer thats hard to spot. According to a new study published in the Journal of the American Academy of Dermatology, this type of skin cancer is becoming more common.
For patients with Merkel cell carcinoma (MCC), predictors of recurrence and survival have been identified which may help to inform diagnostic and therapeutic management.
Merkel cell carcinoma often responds to chemotherapy, but the responses are transient. Prior studies have shown that most patients tumors have progressed by three months from starting chemotherapy, and over 90 percent of patients develop progressive disease within 10 months. In the pembrolizumab trial, 86 percent of patients who responded are still experiencing excellent disease control more than six months after starting therapy, said Dr. Paul Nghiem, affiliate investigator of the Clinical Research Division at Fred Hutchinson Cancer Research Center in Seattle, and professor of medicine, Division of Dermatology at the University of Washington School of Medicine.. This study will be presented on April 19 at the American Association for Cancer Research Annual Meeting 2016 and simultaneously published in The New England Journal of Medicine.. MCC is 35 times less common than melanoma, but on average, it is about three times more likely to be deadly. About 2,000 new cases are diagnosed in the U.S. ...
In a small clinical trial, more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma responded to the immunotherapy drug pembrolizumab.
Question concerns Merkel Cell Carcinoma and CLL. Patient is 63 yo male, dxd with prostate cancer 95 and treated with seeds. PCa metastatic to bone in 99. PCa controlled with double dose Casodex. ...
• A Merkel cell carcinoma of the mandibular area in a 78-year-old woman was treated successfully by direct intratumoral administration of recombinant human tumo
ICD-10 C4A.60 is merkel cell carcinoma of unspecified upper limb, including shoulder (C4A60). This code is grouped under diagnosis codes for neoplasms.
... usually requires a few different tests, which this eMedTV segment explains. Common tests include biopsy, skin exam, blood tests, and a CT scan.
The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC.. According to the National Cancer Institute, approximately 1,600 people in the United States are diagnosed with MCC every year. While the majority of patients present with localized tumors that can be treated with surgical resection, approximately half of all patients will experience recurrence, and more than 30 percent will eventually develop metastatic disease. In patients with metastatic MCC, the cancer has spread beyond the skin into other parts of the body.. Bavencio targets the programmed cell death-ligand PD-1/PD-L1 pathway with potential immune checkpoint inhibitory and anti-cancer activity. When Bavencio binds to PD-L1 it blocks the interaction of PD-L1 with its ...
There is no sure way to prevent Merkel cell skin cancer, but we can reduce the risk and find it if it does occur. Learn more about cancer prevention.
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell...
Learn about this aggressive skin cancer. Find out about symptoms, diagnosis and treatments, including Mohs surgery, radiation and immunotherapy.
Merkel cell polyomavirus (MCPyV) DNA was detected in 88% of Merkel cell carcinomas in contrast to 16% of other skin tumors. MCPyV was also found in anogenital and oral samples (31%) and eyebrow hairs (50%) of HIV-positive men and in forehead swabs (6 ...
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer. Further investigations indicate that senescence does not contribute to MLN0128-mediated repression of xenograft MCC tumor growth. Finally we also observe robust antitumor effects of MLN0128 when administered as a dual therapy with JQ1 a bromodomain protein BRD4 inhibitor. These results suggest dual blockade of PI3K/mTOR pathway and c-Myc axis is effective in the control of MCC tumor growth. Our results demonstrate that MLN0128 is potent as monotherapy or as a member of combination therapy with JQ1 for advanced MCC. culture experiments with MCC cells followed by Western blot analysis. We first treated MCC cells with or without different concentrations of MLN0128 for 24 hours and then examined the total and phosphorylated protein profile of the targeted pathways by Western blotting. Consistent with published reports on other solid tumors MLN0128 markedly inhibited phosphorylation of both mTOR CI994 (Tacedinaline) and its ...
in Oncology Reports (2006), 16(2), 347-352. Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of 18FDG PET in the management of MCC. Eleven patients with MCC ... [more ▼]. Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of 18FDG PET in the management of MCC. Eleven patients with MCC were examined by 18FDG PET and PET-CT for staging purpose (n=4) or for detection of recurrence (n=7). Qualitative and quantitative interpretation of PET studies was performed routinely. 18FDG PET observations were compared to clinical and radiological findings. In 6 patients, PET findings were also compared to histology. In 7 patients, the 18FDG tumor uptake was compared to the MCC proliferative activity expressed by the Ki-67 index. 18FDG PET was contributive in 10/11 MCC patients. In 7 patients, 18FDG PET detected focal lesions or a ...
Background: Merkel cell polyomavirus (PyV) is causally related to Merkel cell carcinoma, a rare skin malignancy. Little is known about the serostability of other PyVs over time, or associations with cutaneous squamous cell carcinoma (SCC). Methods: As part of a US nested case-control study, antibody response against the PyV VP1 capsid proteins of BK and JC was measured using multiplex serology on 113 SCC cases and 229 gender, age, and study center-matched controls who had a prior keratinocyte cancer. Repeated serum samples from controls, and both pre- and post-diagnosis samples from a subset of SCC cases were also tested. Odds ratios (OR) for SCC associated with seropositivity to each PyV type were estimated using conditional logistic regression. Results: Among controls, BK and JC seroreactivity was stable over time, with intraclass correlation coefficients of 0.86 for BK and 0.94 for JC. Among cases, there was little evidence of seroconversion following SCC diagnosis. JC seropositivity prior to ...
None of the four human polymaviruses that were known in early 2008 - JC, BK, KI and WU - had been shown to cause cancer. The subsequent identification of a new polyomavirus associated with Merkel cell carcinoma demonstrates the type of evidence that is required to prove that a virus is oncogenic in humans.. Merkel cell carcinoma (MCC) is a relatively rare human skin cancer, although its incidence has increased in the past twenty years from 500 to 1500 cases per year. This cancer occurs more frequently than expected in individuals who are immunosuppressed, such as those who have received organ transplants or who have AIDS. A similar pattern of susceptibility is also observed for Kaposis sarcoma, a tumor that is caused by the herpesvirus HHV-8. Therefore it was suggested that MCC might also be caused by an infectious agent.. To identify the etiologic agent of MCC, the nucleotide sequence of total mRNA from several MCC tumors was determined and compared with the sequence of mRNA from a normal ...
Merkel cell carcinoma (MCC) is an aggressive, virus-associated, neuroendocrine tumor of the skin mainly affecting immunocompromised patients. Higher intratumoral infiltration with CD3 and CD8 positive T-cells is associated with a better prognosis, highlighting the relevance of the immune system for MCC development and progression. In this study 21 primary MCCs were stained with immune cell markers including CD3, CD4, CD8, CD68, CD20, and S100. Furthermore, tumor-infiltrating neutrophils, tertiary lymphoid structures and PD-L1 expression were analyzed and correlated with overall and recurrence free survival. All MCCs were Merkel Cell Polyomavirus positive. Overall and recurrence-free survival did not correlate with intra-and peritumoral CD3 and CD8 T-cell infiltration. In addition, no significant association regarding prognosis was found for tumor-associated neutrophils, tumor-associated macrophages or PD-L1 positivity in MCCs. Interestingly, the presence of tertiary lymphoid structures (TLS) in ...
Safety data were evaluated in 1,738 patients who received avelumab at 10 mg/kg, every 2 weeks. The most common serious adverse reactions to avelumab are immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, adrenal insufficiency, hypo- and hyperthyroidism, diabetes mellitus, and nephritis) and life-threatening infusion reactions. Among the 88 patients enrolled in the JAVELIN Merkel 200 trial, the most common adverse reactions were fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, rash, decreased appetite, and peripheral edema. Serious adverse reactions that occurred in more than one patient in the trial were acute kidney injury, anemia, abdominal pain, ileus, asthenia, and cellulitis ...
Concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of trial treatment. Short-term administration of systemic steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) while on study is allowed. Also, subjects requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ,= 10 mg or equivalent prednisone per day. Note: Subjects receiving bisphosphonate or denosumab are eligible ...
Merkel cell carcinoma (MCC) is a lethal, virus-associated cancer that lacks effective therapies for advanced disease. Agents blocking the PD-1/PD-L1 pathway have shown objective, durable tumor regressions in patients with advanced solid malignancies and efficacy has been linked to PD-L1 expression in the tumor microenvironment. To investigate whether MCC might be a target for PD-1/PD-L1 blockade, we examined MCC PD-L1 expression, its association with tumor-infiltrating lymphocytes (TIL), Merkel cell polyomavirus (MCPyV), and overall survival. Sixty-seven MCC specimens from 49 patients were assessed with immunohistochemistry for PD-L1 expression by tumor cells and TILs, and immune infiltrates were characterized phenotypically. Tumor cell and TIL PD-L1 expression were observed in 49% and 55% of patients, respectively. In specimens with PD-L1(+) tumor cells, 97% (28/29) showed a geographic association with immune infiltrates. Among specimens with moderate-severe TIL intensities, 100% (29/29) showed ...
Discussion:. Epidemiology and etiology Merkel cell carcinoma (MCC) is a primary cutaneous neuroendocrine carcinoma first described in 1972 as trabecular carcinoma of the skin . Its origin from normal Merkel cells is controversial (1) . Although still rare (fewer than 2 cases per 100,000), MCC has its incidence tripled over the past 15 years. It primarily affects Caucasians, has a mean age at diagnosis of 69 years, and is slightly more common in males (60%). MCC most often occurs in sun exposed areas, with half of the cases in the head and neck. Chronic sun exposure and immunosuppression have been considered risk factors for MCC. The incidence of MCC significantly increases after a diagnosis of certain other malignancies, including melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, chronic lymphocytic leukemia, and lymphomas (2) . Recently, a new polyoma virus, Merkel cell polyoma virus, has been found to clonally integrate at various sites in the human genome of the majority of ...
The Galloway Lab is focused on the role that small DNA viruses play in cancer, including the high risk human papillomaviruses (HPV) in anogenital cancers, genus beta HPVs in squamous cell skin cancers, and the Merkel cell polyomavirus (MCPyV) in Merkel cell carcinomas. We have taken a broad based approach that includes mechanistic studies into how the viral oncoproteins contribute to neoplasia, and molecular epidemiologic studies into the natural history of viral infections and risk factors that are associated with the development of these cancers.. We have sought to determine how the HPV 16 E6 and E7 oncoproteins disrupt the cell cycle checkpoints that normally maintain genomic integrity, and how E6/E7 facilitates the immortalization of primary human cells in culture. In ongoing studies we are interested in how the E6 protein regulates expression of hTERT, the catalytic subunit of telomerase. HPV 16 E6 targets two isoforms of NFX1, promoting degradation of the NFX1-91 transcriptional repressor, ...
Human diseases caused by viruses include the common cold, chickenpox, shingles, influenza, avian influenza, hepatitis, acquired Immunodeficiency syndrome (AIDS), SARS, multiple sclerosis, type I diabetes, and certain types of cancer. Cancer-causing viruses are human papillomavirus, hepatitis B virus, hepatitis C virus, Epstein-Barr virus, Kaposis sarcoma-associated herpesvirus, and human T-lymphotropic virus. Also, Merkel cell polyomavirus causes most cases of a rare form of skin cancer called Merkel cell carcinoma.. The innate immune system is the first line of defense against viruses. RNA interference is an important innate defense mechanism in which the RNA-Inducing Silencing Complex (RISC) degrades the viral mRNA and the cell survives the infection. Adaptive immunity - humoral immunity and cellular immunity, is the second line of defense evoked by virus infection. Many viruses, however, such as human immunodeficiency virus (HIV), can evade the immune system by constantly changing the amino ...
Merkel cell carcinoma (MCC) is an uncommon carcinoma of the epidermal neuroendocrine cells with approximately 1500 cases a year in the United States.1 Merkel cell carcinoma has a poor prognosis with approximately one-third of cases resulting in death within 5 years and with a survival rate strongly dependent on the stage of disease at presentation.2 A complete surgical excision with histologically verified clear margins is the main form of treatment of the primary cancer.3 Although the effectiveness of adjuvant therapy for MCC has been debated,4 retrospective analysis has shown that the high local recurrence rate of the primary tumor can be reduced by combining surgical excision with a form of radiation therapy.5. A systematic cohort study of 195 patients diagnosed with MCC summarized its most clinical factors with the acronym AEIOU: asymptomatic, expanding rapidly, immunosuppression, older than 50 years of age, and UV-exposed site on a fair-skinned individual.6 The role of immune function in ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
A noted New York City dermatologist, Diane S. Berson, MD, can swiftly spot the warning signs of skin cancers. Yet, even she was caught off guard to learn that the shiny, benign-looking, cyst-like bump on her mothers forehead was a Merkel cell carcinoma (MCC), a rare, virulent skin malignancy usually caused by sun exposure. The disease quickly spread to her lymph nodes, and just six months after being diagnosed, Dr. Bersons beloved mother Florence passed away in 2007 from complications of the metastasis and subsequent treatment.. "If this hadnt happened, she would have had an active lifetime ahead," Dr. Berson lamented. "She turned 80 on her first day receiving chemo in the hospital, but was more like an energetic 60-year-old. To the last moment, she was the smartest person Ive ever known. We were very close; she was always the first person I called to get together when I had free time.". Florence was many things throughout her life: an incredibly supportive mother of two daughters, opera ...
Journal of Skin Cancer is a peer-reviewed, Open Access journal that publishes clinical and translational research on the detection, diagnosis, prevention, and treatment of skin malignancies. The journal encourages the submission of original research articles, review articles, and clinical studies related to pathology, prognostic indicators and biomarkers, novel therapies, as well as drug sensitivity and resistance.
As a charity, Action Radiotherapy is entirely reliant on donations to support our work. We are extremely grateful to Varian for providing a charitable donation to support our radiotherapy news service. If you would like to receive a daily email with the latest radiotherapy news, please sign up here. ...
Diagnosis Code C4A.6 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Diagnosis Code C4A.22 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
This is the official approximate match mapping between ICD9 and ICD10, as provided by the General Equivalency mapping crosswalk. This means that while there is no exact mapping between this ICD10 code C4A.71 and a single ICD9 code, 209.34 is an approximate match for comparison and conversion purposes. ...
A small study presented at ECC2015 shows positive responses in patients with Merkel cell carcinoma after few weeks of treatment with checkpoint inhibi
Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformatics approach querying a large compendium of gene expression profiles to identify candidate U.S. Food and Drug Administration (FDA)-approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endogenous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein-coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma. ...
Purpose: Merkel cell carcinoma (MCC) is an aggressive cancer with frequent metastasis and death with few effective therapies. Because programmed death ligand-1 (PD-L1) is frequently expressed in MCC, immune checkpoint blockade has been leveraged as treatment for metastatic disease. There is therefore a critical need to understand the relationships between MCPyV status, immune profiles, and patient outcomes.. Experimental Design: IHC for CD3, CD8, PD-1, PD-L1, and MCPyV T-antigen (to determine MCPyV status) was performed on 62 primary MCCs with annotated clinical outcomes. Automated image analysis quantified immune cell density (positive cells/mm2) at discrete geographic locations (tumor periphery, center, and hotspot). T-cell receptor sequencing (TCRseq) was performed in a subset of MCCs.. Results: No histopathologic variable associated with overall survival (OS) or disease-specific survival (DSS), whereas higher CD3+ (P = 0.004) and CD8+ (P = 0.037) T-cell density at the tumor periphery ...
The 2016 Course on Rare Skin Diseases took place in Zagreb, Croatia on September 22, 2016. It brought together around 80 participants from 15 (...)
This grant will support novel use of a vaccine adjuvant developed by Immune Design Corporation as a cancer therapeutic for Merkel cell carcinoma (MCC). MCC often occurs in the skin, presenting the opportunity to inject adjuvant directly into the tumor. The adjuvant, which will be tested in 10 MCC patients, is expected to recruit immune cells to the tumor to assist the patients own immune system in attacking the cancer. Immune therapies with antibodies have had some recent spectacular successes, and although this is a different approach (no tumor-specific antibodies will be injected), activating the patients immune system shows promise and is generally safer and better tolerated than traditional chemotherapy. Only about 1,600 patients per year develop MCC, but the University of Washington is a center that attracts both in-state and out-of-state patients, and the therapy may ultimately be applicable to other cancers.. Collaborating organizations: Fred Hutchinson Cancer Research Center, Immune ...
A) H&E staining (×2 magnification). B) CK20 staining (×4 magnification); C) CM2B4 LT specific antibody staining (×10 magnification); D) PCR amplification of viral LT gene and capsid (VP) DNA sequences from different central (C) and peripheral (P) areas of the tumour. N: no DNA; MW: molecular weight VIII (Roche, Milan, Italy). The arrows indicate the position of the expected amplified products. The presence of larger and smaller LT1 amplified products is related to mispriming. E) RCA of freshly extracted DNA. In lane T (tumour), a single band is present that corresponds to a product that is larger than that expected for a polyomavirus and similar to that of a papillomavirus (marked with arrows). MW: molecular weight DM013-R500 (Gene-DireX, USA). F) PCR amplification of viral LT and capsid genes of MCPyV using DNA extracted from two low-passage cell clones (1 and 3). G) PCR amplification with CP primers. T: DNA from MCC; N: no DNA added; C+: positive control for HPV amplification; MW: molecular ...
Dr. Amy Coxon applies her expertise in molecular biology, mouse genetics, and xenograft models to investigate the pathobiology of merkel cell carcinoma (MCC) with the goal of identifying novel therapeutic targets.
Drugs Approved in 2017. Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell lung cancer, Approved April 2017. Bavencio (avelumab); EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma, Approved March 2017. Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma, Approved May 2017. Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017. Nerlynx (neratinib); Puma Biotech; For the treatment of HER2 breast cancer, Approved July 2017. Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017. Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017. Zejula (niraparib);. Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017. Drugs Approved in ...
1279 Sumatriptan succinate. after renal suhagra 100 nebenwirkungen cardiac transplanta- tion, in rheumatoid arthritis), chronic lymphocytic leukemia and chronic sunlight and arsenic exposure predispose also younger individuals and non-Caucasians to develop Merkel cell carcinoma.
NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, and non-hodgkin lymphoma and myelodysplastic syndrome.. ...
Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with advanced solid tumors. Experimental Design: In a 3+3 dose escalation study, 10 patients received pembrolizumab 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) until progression or intolerable toxicity. Seven additional patients received 10 mg/kg Q2W. Thirteen patients participated in a 3-week intrapatient dose escalation (dose range, 0.005‒10 mg/kg) followed by 2 or 10 mg/kg Q3W. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Results: No dose-limiting toxicities were observed. Maximum administered dose was 10 mg/kg Q2W. One patient with melanoma and 1 with Merkel cell carcinoma experienced complete responses of 57 and 56+ weeks duration, respectively. Three patients with melanoma experienced partial responses. Fifteen patients with various malignancies experienced stable ...
Dr Tothill is a PhD trained cancer biologist specializing in the genomic analysis human tumours. He has worked extensively on the genomic analysis of solid adult cancers including ovarian cancer, cancer of unknown primary, melanoma, Merkel cell carcinoma and phaeochromocytoma/paraganglioma (PPGL). His work and expertise involves a range of genomics methods including DNA sequencing, transcriptomics and epigenetics, incorporating histopathology, biochemistry and model systems for validation studies. His recent research has included publications describing the mutational landscape of PPGL and the development of a gene-expression diagnostic method to be used as an adjunct to PPGL genetic testing.. ...
Gordon has Merkel Cell Carcinoma and we need help funding immunotherapy treatment so he can continue on with his life. - Givealittle is the place to donate and fundraise for causes and charities online.
David Barry Brudnoy (June 5, 1940 - December 9, 2004) was an American talk radio host in Boston from 1976 to 2004. His radio talk show aired on WBZ radio. He was known for espousing his libertarian views on a wide range of political issues, in a manner that was courteous. Thanks to WBZs wide signal reach, he gained a following from across the United States as well as Canada. On December 9, 2004, he succumbed to Merkel cell carcinoma after it had metastasized to his lungs and kidneys. Born in Minneapolis, Minnesota, United States, to a Jewish family, David Brudnoy was the only child of Doris and Harry Brudnoy. Harry was a dentist in the Minneapolis area, a profession he maintained for over 50 years. During his youth, David Brudnoy was known to be precocious, and in addition to reading a lot, he enjoyed collecting stamps. He was also interested in history, and thanks to the influence of his Aunt Kathie, with whom he was close for all of his life, he became interested in movies; he often attended ...
written by Sandra Batie, Susan B. Carter, Roger Ransom. Richard Charles Sutch, Distinguished Professor Emeritus, Economics, University of California Riverside and Research Associate of the National Bureau of Economic Research, died peacefully on September 19, 2019 at his home in Kensington, California. The cause of death was merkel cell carcinoma. He was 76 years old.. Sutch will be remembered as a gregarious, exuberant, creative, hardworking, and witty person filled with love for family, colleagues, and friends. He loved to gather people together for evenings of his wonderful gourmet meals punctuated with good wine and great conversation. When traveling he always knew the best restaurants and would frequently include a side trip to a unique food-oriented site-such as an oyster shucking plant. He will be missed by many.. Professor Sutch made enduring contributions in a variety of fields. As a high school student he was a founding member of the Richland (WA) Rocket Society, the first amateur ...
Kenneth Daily, Amy Coxon, Daniel G Coit, Klaus J Busam, Isaac Brownell. "Genome-wide copy number analysis of Merkel cell carcinoma ...
Park DEsther, Cheng J, Berrios C, Montero J, Cortés-Cros M, Ferretti S, Arora R, Tillgren ML, Gokhale PC, DeCaprio JA. 2019. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.. Proc Natl Acad Sci U S A. 116(3):1027-1032. ...
Join the fight against Merkel cell carcinoma. Support the work of the Nghiem Lab at the University of Washington by making a tax-deductible donation.
Almost 300,000 people worldwide develop malignant melanoma each year. The disease is the most serious form of skin cancer and the number of cases reported annually is increasing, making skin cancer one of Swedens most common forms of cancer. A research team at Lund University in Sweden has studied a protein that regulates a gene which is linked to metastasis of malignant melanoma.
The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, a new study has revealed.
GREENWOOD (KFSM) -- A Greenwood coach who was diagnosed with a rare skin condition has made a turn for the better, according to his wifes Facebook post. Belinda Sims said coach Brian Sims had a successful surgery and that his skin is starting to heal and form skin buds.
In spite of a rare skin disease that leaves him vulnerable to even the smallest bump, one 16-year-old Connecticut teen still dreams to of being a train engineer.
This contest aims at raising awareness about rare skin diseases and allowing people to express their feelings about this issue in a different (...). ...
Raoul de Villiers died peacefully at his home on 12 April 2014. He had bravely battled an unusual Merkel cell tumour, uncomplainingly putting up with surgery and radiation over the last four years of his life. Ultimately, however, he succumbed to this disease.. Raoul was born in Stellenbosch on 15 April 1927 and schooled at Stellenbosch High School for Boys (known as Paul Roos Gymnasium today). His interests were always in the scientific field, so he did a BSc degree at Stellenbosch University, passing cum laude in 1946. He then changed universities and did an MSc in physiology at the University of Cape Town. His thesis was on the pancreatic structure of the shark (which presumably gave him the opportunity to spend time fishing while obtaining a higher degree!). He was awarded the MSc with first-class honours.. Raoul now wanted to do medicine, so he enrolled at UCT as a medical student. He qualified in 1952 with top honours and a gold medal in obstetrics. After graduation he decided to be a ...
Results KI, WU and MCV were detected in 9.2%, 12.3% and 33.8% of specimens, respectively; with mean viral load ranging from 81 copies/104 cells for WU to 258 for MCV, thus not differing from that previously reported in native lungs. No significant association with clinical and histopathological findings (including acute respiratory insufficiency, interstitial and organising pneumonia, acute and chronic rejection) was found. ...
To test the hypothesis that Merkel cell polyomavirus (MCPyV) can infect cells of the lymphoid system, we analyzed 353 specimens, including 152 non-Hodgkin lymphomas, 44 Hodgkin lymphomas, 110 benign lymph nodes, 27 lymph nodes with metastasis, and 20 extranodal tissue samples. MCPyV DNA was detected by quantitative PCR in 13 (6.6%) of 196 lymphomas, including 5 (20.8%) of 24 chronic lymphocytic leukemia specimens, and in 11 (10%) of 110 benign lymph nodes, including 8 (13.1%) of 61 samples of reactive hyperplasia and 3 (10.3%) of 29 normal lymph nodes. Other samples were MCPyV negative. Sequence analysis of 9 virus-positive samples confirmed the identity of MCPyV; 3 viral strains were represented. Immunohistochemical testing showed that 1 T-cell lymphoma expressed MCPyV T-antigen. These findings suggest that the lymphoid system plays a role in MCPyV infection and may be a site for MCPyV persistence.
Over the past 8 years, the discovery of 11 new human polyomaviruses (HPyVs) has revived interest in this DNA tumor virus family. Although HPyV infection is widespread and largely asymptomatic, one of these HPyVs, Merkel cell polyomavirus (MCV), is a bona fide human tumor virus. JC virus (JCV), BK virus, HPyV7, and trichodysplasia-spinulosa virus (TSV) can cause nonneoplastic diseases in the setting of immunosuppression. Few specific reagents are available to study the biology of the newly discovered HPyVs. We developed a pan-HPyV-screening method using a cocktail of 3 antibodies that, when combined, recognize T antigen proteins of all HPyVs. We validated detection characteristics of the antibody cocktail by immunoblotting and immunohistochemistry and screened 1,184 cases, including well-defined diseases and tumor tissue microarrays. This assay robustly detected MCV, TSV, JCV, and HPyV7 in etiologically related diseases. We further identified WU polyomavirus in a case of chronic lymphocytic ...
We identified a new polyomavirus in skin lesions from a patient with trichodysplasia spinulosa (TS). Apart from TS being an extremely rare disease, little is known of its epidemiology. On the basis of knowledge regarding other polyomaviruses, we anticipated that infections with trichodysplasia spinulosa-associated polyomavirus (TSV) occur frequently and become symptomatic only in immunocompromised patients. To investigate this hypothesis, we developed and used a Luminex-based TSV viral protein 1 immunoassay, excluded cross-reactivity with phylogenetically related Merkel cell polyomavirus, and measured TSV seroreactivity. Highest reactivity was found in a TS patient. In 528 healthy persons in the Netherlands, a wide range of seroreactivities was measured and resulted in an overall TSV seroprevalence of 70% (range 10% in small children to 80% in adults). In 80 renal transplant patients, seroprevalence was 89%. Infection with the new TSV polyomavirus is common and occurs primarily at a young age.
Merkel-cell carcinoma is a rare and highly aggressive skin cancer, which, in most cases, is caused by the Merkel cell polyomavirus (MCV) discovered by scientists at the University of Pittsburgh in 2008. It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, and trabecular carcinoma of the skin. ...
She said: "I have goals like anyone else. I want to study like them … its very unpleasant to see how others can enjoy life, and I cant myself.". Merkel responded by saying she understood, but that "politics is sometimes hard. Youre right in front of me now and youre an extremely sympathetic person. But you also know in the Palestinian refugee camps in Lebanon are thousands and thousands and if we were to say you can all come … we just cant manage it.". The chancellor said she hoped the decision-making process, as to which refugees could stay and which must return, would soon be made quicker. But she was forced to stop mid-sentence, and muttered "oh Gott", on seeing that Reem was crying. She walked up to the girl and started stroking her shoulder, saying: "You were great … I know its difficult for you and you presented extremely well the situation that many others find themselves in.". The incident, which was trending on Twitter as #MerkelStreichelt (Merkel strokes), coincided with ...
PURPOSE OF REVIEW Metastatic melanoma is the most aggressive skin cancer and despite tremendous efforts and considerable progress in clinical treatment of melanoma patients within recent years, it remains a deadly disease. Current treatments affect melanoma cells indiscriminately, while accumulating evidence suggests that melanoma might be a disease of stem cells. This review aims to summarize the important accomplishments in the field and to emphasize the common molecular and cellular mechanisms regulating self-renewal of neural crest stem cells (NCSCs) and melanoma cells. RECENT FINDINGS A growing number of publications highlight the existence of phenotypic and functional similarities between embryonic NCSCs and melanoma cells. These studies provide compelling evidence that the propagation of melanoma cells critically depends on genes instrumental in neural crest development. The example of Sox10 and Rac1 genes provides detailed illustration of how interfering with these important genes for ...
Dr. Kelly Harms, MD, PhD, is an Assistant Professor in the Department of Dermatology at the University of Michigan Health System. She provides patient care in our Cutaneous Surgery and Oncology clinical programs, including the Mohs surgery clinic and multidisciplinary melanoma and cutaneous oncology clinics located within the UM Comprehensive Cancer Center. Dr. Harms is a board-certified dermatologist and ACGME Fellowship-trained Mohs Surgeon, with specialized training and expertise in treating high-risk skin cancer. Dr. Harms joined the Dermatology faculty in 2014, upon completing her ACGME procedural dermatology fellowship, with advanced training in melanoma and cutaneous surgery and oncology at the University of Michigan Comprehensive Cancer Center. Her clinical work is focused on Mohs surgery and associated reconstruction, as well as the complex management of patients seen within our Multidisciplinary Melanoma and Merkel Cell Programs. Dr. Harms received her medical degree from the ...
AIMS: Neuroblastoma shows considerable histological overlap with other small round blue cell tumours. PHOX2B, a transcription factor that is essential for autonomic nervous system development, has been reported as an immunohistochemical marker for neuroblastoma. The aim of this study was to validate the specificity and diagnostic utility of PHOX2B for peripheral neuroblastic tumours. METHODS AND RESULTS: We evaluated 240 cases (133 in whole-tissue sections; 107 in tissue microarrays), including 76 peripheral neuroblastic tumours (median age 2 years; including four adults) and 164 other tumours: 44 Wilms tumours; 20 Ewing sarcomas; 10 each of CIC-rearranged round cell sarcomas, poorly differentiated synovial sarcomas, lymphoblastic lymphomas, alveolar rhabdomyosarcomas, embryonal rhabdomyosarcomas, mesenchymal chondrosarcomas, Merkel cell carcinomas, olfactory neuroblastomas, and melanomas; and five each of NUT midline carcinomas and desmoplastic small round cell tumours ...
TY - JOUR. T1 - ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. AU - Augustyn, Alexander. AU - Borromeo, Mark. AU - Wang, Tao. AU - Fujimoto, Junya. AU - Shao, Chunli. AU - Dospoy, Patrick D.. AU - Lee, Victoria. AU - Tan, Christopher. AU - Sullivan, James P.. AU - Larsen, Jill E.. AU - Girard, Luc. AU - Behrens, Carmen. AU - Wistuba, Ignacio I.. AU - Xie, Yang. AU - Cobb, Melanie H.. AU - Gazdar, Adi F.. AU - Johnson, Jane E.. AU - Minna, John D.. AU - Vogt, Peter K.. PY - 2014/10/14. Y1 - 2014/10/14. N2 - Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset that accounts for approximately 40,000 new lung cancer cases per year in the United States. No targeted therapy exists for these tumors. We determined that achaetescute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is ...

Findings Support Use of Avelumab in Metastatic Merkel Cell CarcinomaFindings Support Use of Avelumab in Metastatic Merkel Cell Carcinoma

... according to findings from the phase II JAVELIN Merkel 200 trial presented at the 2016 ASCO Annual Meeting. ... Avelumab showed early positive survival data and lasting responses for patients with pretreated advanced or metastatic Merkel ... in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel ... In addition to Merkel cell carcinoma, avelumab is also being explored across a variety of other types of cancer that have shown ...
more infohttp://www.targetedonc.com/conference/asco-immune-2016/findings-support-use-of-avelumab-in-metastatic-merkel-cell-carcinoma

Avelumab for metastatic Merkel cell carcinoma after chemotherapy. Avelumab for metastatic Merkel cell carcinoma after...Avelumab for metastatic Merkel cell carcinoma after chemotherapy. Avelumab for metastatic Merkel cell carcinoma after...

... group that many Merkel cell carcinomas were associated with the expression of PD-L1 either on the tumour cell or other cells ... Avelumab for metastatic Merkel cell carcinoma after chemotherapy. Please rate this video. Please complete at least one question ... So if you dont know about Merkel cell carcinoma its a fairly rare but very aggressive form of skin cancer and has been ... Avelumab is a humanised anti-PD-L1 antibody and so the rationale for using this in Merkel cell carcinoma really began with a ...
more infohttp://ecancer.org/video/5866/avelumab-for-metastatic-merkel-cell-carcinoma-after-chemotherapy.php

Recurrence of Merkel cell carcinoma in the gastrointestinal tract: a case report | BMC Research Notes | Full TextRecurrence of Merkel cell carcinoma in the gastrointestinal tract: a case report | BMC Research Notes | Full Text

Metastatic Merkel cell carcinoma to the gastrointestinal tract or any other organ should be considered in patients with a ... There are only a few cases in the literature reporting metastases of Merkel cell carcinoma to the gastrointestinal tract. We ... the evaluation of anemia revealed 1 cm polyp in ascending colon which turned out to be the recurrence of Merkel cell carcinoma ... present a 70 year old Caucasian female with distant history of Merkel cell carcinoma who presented with iron-deficiency anemia ...
more infohttps://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-015-1139-3/figures/2

Merck: European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma | BioRN - Biotech-Cluster Rhine...Merck: European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma | BioRN - Biotech-Cluster Rhine...

Merck: European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma. Home ,, Press Releases ,, Merck: ... for Metastatic Merkel Cell Carcinoma ...
more infohttp://biorn.org/merck-european-commission-approves-bavencio-avelumab-for-metastatic-merkel-cell-carcinoma/

Merkel Cell  Carcinoma Risk FactorsMerkel Cell Carcinoma Risk Factors

This guide will help you learn about possible causes of Merkel cell skin cancer. ... Many risk factors may increase your chance of developing Merkel cell skin cancer. ... Merkel cell polyomavirus (MCV) infection. The Merkel cell polyomavirus (MCV) is found in the cancer cells of about 8 out of 10 ... Merkel Cell Carcinoma Risk Factors. A risk factor is anything that raises your chance of getting a disease such as cancer. ...
more infohttps://www.cancer.org/cancer/merkel-cell-skin-cancer/causes-risks-prevention/risk-factors.html

Can Merkel Cell Carcinoma Be Prevented?Can Merkel Cell Carcinoma Be Prevented?

There is no sure way to prevent Merkel cell skin cancer, but we can reduce the risk and find it if it does occur. Learn more ... Can Merkel Cell Carcinoma Be Prevented?. The risk of getting Merkel cell carcinoma (MCC) is low, and some risk factors for MCC ... Merkel Cell Carcinoma Risk Factors * What Causes Merkel Cell Carcinoma? * Can Merkel Cell Carcinoma Be Prevented? ... Merkel Cell Carcinoma Risk Factors * What Causes Merkel Cell Carcinoma? * Can Merkel Cell Carcinoma Be Prevented? ...
more infohttps://www.cancer.org/cancer/merkel-cell-skin-cancer/causes-risks-prevention/prevention.html

FDA approves pembrolizumab for Merkel cell carcinoma | FDAFDA approves pembrolizumab for Merkel cell carcinoma | FDA

Inc.) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). ... Inc.) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). ...
more infohttps://www.fda.gov/drugs/fda-approves-pembrolizumab-merkel-cell-carcinoma?utm_campaign=Oncology%2012%2F19%2F2018%20pembrolizumab&utm_medium=email&utm_source=Eloqua&elqTrackId=6be7b4948c4141c0ac00d8e340dde28a&elq=50cde781d4854ad685465103861899f6&elqaid=6339&elqat=1&elqCampaignId=5170

Merkel Cell Carcinoma Metastasis - Cancer - MedHelpMerkel Cell Carcinoma Metastasis - Cancer - MedHelp

Question concerns Merkel Cell Carcinoma and CLL. Patient is 63 yo male, dxd with prostate cancer 95 and treated with seeds. ... Merkel Cell Carcinoma Metastasis. Question concerns Merkel Cell Carcinoma and CLL. Patient is 63 yo male, dxd with prostate ... Patient dxd with Merkel Cell Carcinoma 07. Merkel cell treated unsuccessfully with chemo and successfully with radiation. ... Patient dxd with Merkel Cell Carcinoma 07. Merkel cell treated unsuccessfully with chemo and successfully with radiation. ...
more infohttp://www.medhelp.org/posts/Cancer/Merkel-Cell-Carcinoma-Metastasis/show/561937

Immunotherapy Should Be First Line in Merkel Cell CarcinomaImmunotherapy Should Be First Line in Merkel Cell Carcinoma

The authors also acknowledge support from the Merkel cell carcinoma patient gift fund at University of Washington; the Kelsey ... Upfront immunotherapy with pembrolizumab (Keytruda, Merck & Co) in patients with advanced Merkel cell carcinoma (aMCC) shows an ... Immunotherapy Should Be First Line in Merkel Cell Carcinoma - Medscape - Mar 18, 2019. ... Fast Five Quiz: How Much Do You Know About Merkel Cell Carcinoma? ...
more infohttps://www.medscape.com/viewarticle/910547

Merkel Cell Carcinoma News, Research - Page 3Merkel Cell Carcinoma News, Research - Page 3

... the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel Cell Carcinoma ... identify the embryonic origin of Merkel cells. Their research continue on an extremely aggressive cancer, the Merkel cell ... Researchers identify oncoprotein that allows MCV virus to trigger Merkel Cell Carcinoma Researchers at the University of ... a common and usually harmless virus to transform healthy cells into a rare but deadly skin cancer called Merkel Cell Carcinoma. ...
more infohttps://www.news-medical.net/?tag=/Merkel-Cell-Carcinoma&page=3

Imaging in Patients with Merkel Cell CarcinomaImaging in Patients with Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine tumor of the skin with a mortality rate of approximately 25% ( ... S. Brodsky, J. S. Zager, and C. G. Berman, "Imaging of merkel cell carcinoma," in Merkel Cell Carcinoma: A Multidisciplinary ... To date, there is still no imaging algorithm for Merkel cell carcinoma. Due to the rarity of Merkel cell carcinoma imaging, ... algorithms in patients with Merkel cell carcinoma and no widely accepted guidelines for imaging of Merkel cell carcinoma are ...
more infohttps://www.hindawi.com/journals/jsc/2013/973123/

Merkel Cell Carcinoma Recurrence | MoffittMerkel Cell Carcinoma Recurrence | Moffitt

If Merkel cell carcinoma does come back, unusual skin changes can often be detected in their earliest stages during follow-up ... Merkel cell carcinoma survivors are also advised to complete regular self-exams to check for the potential signs of a ... Because Merkel cell carcinomas are uncommon and the warning signs can be difficult to detect, survivors are encouraged to find ... Anyone who is displaying signs of a potential Merkel cell carcinoma recurrence can turn to Moffitt Cancer Center for prompt ...
more infohttps://moffitt.org/cancers/merkel-cell-carcinoma/recurrence/

Pembrolizumab for Merkel Cell Carcinoma - National Cancer InstitutePembrolizumab for Merkel Cell Carcinoma - National Cancer Institute

... more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma responded to the ... About 80 percent of Merkel cell carcinomas are associated with infection by a virus called Merkel cell polyomavirus (MCPyV). ... The Merkel cell carcinoma study raises the question of whether other viruses that are associated with cancer produce antigens ... In a small clinical trial, more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma ...
more infohttps://www.cancer.gov/news-events/cancer-currents-blog/2016/pembrolizumab-merkel-cell

Secondary Merkel Cell Carcinoma Manifested in the ParotidSecondary Merkel Cell Carcinoma Manifested in the Parotid

Merkel cell carcinoma of the head and neck is a rare and aggressive malignant tumour. Both the dermatological and surgical ... Potential secondary Merkel cell carcinoma in the head and neck region should be taken into account when planning short- and ... Secondary Merkel Cell Carcinoma Manifested in the Parotid. M. Basati, K. Kassam, and A. Messiha ... Histological analysis confirmed Merkel cell carcinoma and consequently surgical excision was carried out. A follow-up PET/CT ...
more infohttps://www.hindawi.com/journals/cridm/2013/960140/abs/

Merkel cell carcinoma - Symptoms and causes - Mayo ClinicMerkel cell carcinoma - Symptoms and causes - Mayo Clinic

Its not clear what causes Merkel cell carcinoma. Merkel cell carcinoma begins in the Merkel cells. Merkel cells are found at ... Merkel cell carcinoma. Merkel cell carcinoma. Merkel cell carcinoma is a rare, aggressive skin cancer. It appears as a painless ... Merkel cell carcinoma is also called neuroendocrine carcinoma of the skin.. Merkel cell carcinoma most often develops in older ... Even with treatment, Merkel cell carcinoma commonly spreads (metastasizes) beyond the skin. Merkel cell carcinoma tends to ...
more infohttps://www.mayoclinic.org/diseases-conditions/merkel-cell-carcinoma/symptoms-causes/syc-20351030

Merkel Cell Carcinoma Surgery | Moffitt Cancer CenterMerkel Cell Carcinoma Surgery | Moffitt Cancer Center

Merkel Cell Carcinoma Surgery Surgery is typically the primary treatment for Merkel cell carcinoma. The most often-recommended ... Merkel cell carcinoma surgery often requires a significant amount of specialized expertise, as this cancer is prone to ... When evaluating a patient for Merkel cell carcinoma surgery, an oncologist will typically:. *Check the lymph nodes for signs of ... Patients who are considering Merkel cell carcinoma surgery can call 1-888-663-3488 or submit a new patient registration form ...
more infohttps://moffitt.org/cancers/merkel-cell-carcinoma/surgery/

Documents | Avelumab for treating metastatic Merkel cell carcinoma | Guidance | NICEDocuments | Avelumab for treating metastatic Merkel cell carcinoma | Guidance | NICE

Avelumab for treating metastatic Merkel cell carcinoma. Technology appraisal guidance [TA517]. Published date: 11 April 2018. ... Merkel cell carcinoma (skin cancer) in adults ...
more infohttps://www.nice.org.uk/guidance/ta517/history

Merkel Cell Carcinoma Treatment (PDQ®) (Health professionals) | OncoLinkMerkel Cell Carcinoma Treatment (PDQ®) (Health professionals) | OncoLink

Merkel Cell Carcinoma Treatment. Merkel cell carcinoma. General Information About Merkel Cell Carcinoma. Merkel cell carcinoma ... Merkel Cell Carcinoma Merkels Cell Carcinoma Small Cell Carcinoma Tonsillar Squamous Cell Cancer in Dogs Squamous Cell ... recurrent Merkel cell carcinoma. Recurrent Merkel Cell Carcinoma Treatment. Merkel cell carcinoma is a rare tumor. There are no ... stage III Merkel cell carcinoma. Stage III Merkel Cell Carcinoma Treatment. Stage III Merkel cell carcinoma (MCC)includes ...
more infohttps://www.oncolink.org/healthcare-professionals/nci/pqid-CDR00000628842

What other terms have been used to refer to Merkel cell carcinoma (MCC)?What other terms have been used to refer to Merkel cell carcinoma (MCC)?

... small cell tumor of the skin, primary undifferentiated carcinoma of the sk... more ... Since then, it has been referred to as cutaneous neuroendocrine carcinoma, ... Detection of Merkel cell polyomavirus in Merkel cell carcinomas and small cell carcinomas by PCR and immunohistochemistry. ... Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require ...
more infohttps://www.medscape.com/answers/853565-10485/what-other-terms-have-been-used-to-refer-to-merkel-cell-carcinoma-mcc

Merkel Cell Carcinoma Treatment (PDQ®)-Health Professional Version - National Cancer InstituteMerkel Cell Carcinoma Treatment (PDQ®)-Health Professional Version - National Cancer Institute

Get detailed information about the diagnosis and treatment of newly diagnosed and recurrent Merkel cell carcinoma in this ... Merkel cell carcinoma treatment options include surgery, radiation therapy, and chemotherapy. ... General Information About Merkel Cell Carcinoma Go to Patient Version Merkel cell carcinoma (MCC) was originally described by ... Recurrent Merkel Cell Carcinoma Treatment. Merkel cell carcinoma is a rare tumor. There are no clinical trials reported for ...
more infohttps://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq/

Find a Merkel Cell Carcinoma Expert | Memorial Sloan Kettering Cancer CenterFind a Merkel Cell Carcinoma Expert | Memorial Sloan Kettering Cancer Center

... including rare skin cancers like Merkel cell carcinoma. We also have experience in managing complex, multiple, and recurrent ... Merkel Cell Carcinoma More About Merkel Cell Carcinoma Diagnosis & Treatment at Memorial Sloan Kettering ...
more infohttps://www.mskcc.org/cancer-care/types/merkel-cell-carcinoma/merkel-cell-carcinoma-expert

Avelumab for treating metastatic Merkel cell carcinoma | Guidance and guidelines | NICEAvelumab for treating metastatic Merkel cell carcinoma | Guidance and guidelines | NICE

Avelumab for treating metastatic Merkel cell carcinoma. Technology appraisal guidance [TA517]. Published date: 11 April 2018. ... 1.1 Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or ... 1.2 Avelumab is recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in ... Treatment options for metastatic Merkel cell carcinoma are limited. People are usually offered chemotherapy or best supportive ...
more infohttps://www.nice.org.uk/guidance/ta517/chapter/1-Recommendations

FDA Approves Bavencio for Merkel Cell CarcinomaFDA Approves Bavencio for Merkel Cell Carcinoma

... Bavencio (avelumab), a PD-L1-inhibitor, gained approval by the Food and Drug ... for the treatment of adult and pediatric patients over the age of 12 with metastatic Merkel cell carcinoma, including those who ... "While skin cancer is one of the most common cancers, patients with a rare form called Merkel cell cancer have not had an ... Overall, 65.9 percent of patients were PD-L1-positive and 52.3 percent were positive for the Merkel cell polyomavirus (MCPyV). ...
more infohttps://www.curetoday.com/articles/fda-approves-bavencio-for-merkel-cell-carcinoma

MC polyomavirus is frequently present in Merkel cell carcinoma of European patients.  - PubMed - NCBIMC polyomavirus is frequently present in Merkel cell carcinoma of European patients. - PubMed - NCBI

MC polyomavirus is frequently present in Merkel cell carcinoma of European patients.. Becker JC, Houben R, Ugurel S, Trefzer U ... Getting stronger: the relationship between a newly identified virus and Merkel cell carcinoma. [J Invest Dermatol. 2009] ... Carcinoma, Merkel Cell/diagnosis*. *Carcinoma, Merkel Cell/epidemiology. *Carcinoma, Merkel Cell/virology* ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/18633441?dopt=Abstract

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma - Full Text View - ClinicalTrials.govCabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma - Full Text View - ClinicalTrials.gov

Carcinoma, Merkel Cell. Carcinoma. Skin Neoplasms. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms ... Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma. The safety and scientific validity of this study is the ... Must have histologically or cytologically confirmed Merkel Cell Carcinoma that is metastatic or unresectable and for which ... Genetic and Rare Diseases Information Center resources: Merkel Cell Carcinoma Neuroendocrine Tumor Neuroepithelioma ...
more infohttps://clinicaltrials.gov/ct2/show/NCT02036476
  • Upfront immunotherapy with pembrolizumab ( Keytruda , Merck & Co) in patients with advanced Merkel cell carcinoma (aMCC) shows an improved overall survival and response rate when compared with historical controls, and has a generally manageable safety profile, according to new findings. (medscape.com)
  • SEER = Surveillance, Epidemiology, and End Results Program.aAlbores-Saavedra J et al: Merkel cell carcinoma demographics, morphology, and survival based on 3,870 cases: A population-based study. (oncolink.org)
  • To determine progression-free survival and overall survival of patients receiving cabozantinib for Merkel Cell Carcinoma. (clinicaltrials.gov)
  • Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. (onclive.com)
  • Given the ability of pembrolizumab to extend survival for some patients with advanced Merkel cell carcinoma, what's the overall outlook in this malignancy? (ascopost.com)
  • You mentioned that the presence of CD8 T cells confers virtually a 100% probability of survival. (ascopost.com)
  • A new data set is informative as to stage-specific survival and can be accessed online at www.merkelcell.org/prognosis/index.php . (ascopost.com)
  • This required an intact retinoblastoma protein-targeting domain that activated survivin gene transcription as well as expression of other G 1 -S-phase proteins including E2F1 and cyclin E. Survivin expression is critical to the survival of MCV-positive MCC cells. (sciencemag.org)
  • High intratumoral numbers of CD3 + , CD8 + , or FoxP3 + cells, and high CD8 + /CD4 + or FoxP3 + /CD4 + ratios, were significantly associated with favorable overall survival. (aacrjournals.org)
  • High intratumoral numbers of CD3 + , CD8 + , and FoxP3 + lymphocytes were each significantly associated with favorable overall survival of patients diagnosed with MCC, and a high tumor CD3 + cell count had independent influence on survival in a Cox multivariable model. (aacrjournals.org)
  • No histopathologic variable associated with overall survival (OS) or disease-specific survival (DSS), whereas higher CD3 + ( P = 0.004) and CD8 + ( P = 0.037) T-cell density at the tumor periphery associated with improved OS. (aacrjournals.org)
  • Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. (springermedizin.at)
  • KEYNOTE-017 represents the longest observation to date of patients with advanced Merkel cell carcinoma receiving anti-PD-1 therapy in the first-line setting, and demonstrated durable tumor control in these patients. (ajmc.com)
  • The primary objectives of this study are to assess 1) the safety and 2) efficacy of combining Anti-PD-1/PD-L1 blockade with palliative radiation therapy in patients with Stage IV Merkel Ce. (bioportfolio.com)
  • NantKwest's phase II immunotherapy trial builds upon the company's earlier phase II single-combination study using its proprietary, off-the-shelf aNK TM natural killer cell therapy and IL-15/Fc superagonist (N-803), which produced an objective responses in 3 of 7 patients. (biospace.com)
  • Commenting on the initiation of this novel triple combination trial in MCC, Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest said, "Even in a heavily pretreated patient population, including patients who have failed checkpoint inhibitor therapy, we were encouraged to see our combination of aNK cell and N-803 therapy exhibit preliminary clinically meaningful antitumor activity, including objective response in this resistant setting. (biospace.com)
  • NantKwest's haNK cell therapy platform is a natural killer cell therapy that was developed to optimize the key role of natural killer cells in mediating innate immunity, enhancing adaptive immune responses, and, specifically in the case of haNK, improve anti-tumor responses via antibody-dependent cell-mediated cytotoxicity (ADCC). (biospace.com)
  • Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon? (mdpi.com)
  • Merkel cell carcinoma: epidemiology, target, and therapy. (andhranews.net)